Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Estimated Industry Valuation for the Remicade Biosimilar Sector?

Recent years have seen tremendous growth in the remicade biosimilar market size. It is projected to escalate from $3.95 billion in 2024 to $4.89 billion in 2025, flourishing at a compound annual growth rate (CAGR) of 23.8%. The phenomenal expansion during the historic period is primarily attributed to factors such as the launch of remicade (infliximab), advancements in biotechnology, the expiration of biologics patents, establishment of regulatory pathways, and the pressure of healthcare costs.

The market size for the remicade biosimilar is predicted to experience a significant escalation in the coming years. It is projected to reach “$10.89 billion by 2029, growing at a compound annual growth rate (CAGR) of 22.2%. The anticipated expansion during the forecast period is attributed to various factors such as patent expiry, increased need for affordable treatments, the development of biosimilar pipelines, reimbursement policies, and market consolidation. Key trends during this period are expected to be physician prescription habits, management of the biosimilar lifecycle, naming protocols for biosimilars, interchangeability of biosimilars, and real-world evidence of biosimilars.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11952&type=smp

What Forces Are Driving The Growth Of The Remicade Biosimilar Market?

The remicade biosimilar market is anticipated to expand due to an increase in the prevalence of autoimmune diseases. These conditions involve the immune system erroneously damaging the body’s tissues and organs. As an effective treatment option, remicade biosimilars are used to manage the symptoms and lower the inflammation that comes with these diseases. For example, according to Public Health Scotland’s data in July 2023, in 2022, the number of newly diagnosed multiple sclerosis (MS) patients rose to 87.2%, an increase from 85.7% in 2020, with 491 new cases documented, adding up to a total of 6,359. Therefore, the escalating prevalence of autoimmune diseases is proving to be a significant growth driver for the remicade biosimilar market.

The remicade biosimilar market covered in this report is segmented –

1) By Type: 100mg/10ml, 500mg/50ml

2) By Disease Indication: Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Crohn’s Disease, Psoriatic Arthritis, Plaque Psoriasis

3) By Application: Blood Disorders, Oncology Diseases

Subsegments:

1) By 100 Mg/10 Ml: Vials For Injection, Prefilled Syringes

2) By 500 Mg/50 Ml: Vials For Injection, Prefilled Syringes

What Long-Term Trends Are Likely To Affect The Remicade Biosimilar Market?

A prominent trend in the Remicade biosimilar market is product innovation, with leading companies endeavouring to create novel products to maintain their market standing. For example, in January 2023, Amgen Inc., a biotech firm based in the US, released Amjevita, a biosimilar of AbbVie’s Humira that matches the original drug’s safety and effectiveness. This version is the inaugural biosimilar of Humira and aims to vie with Humira for market visibility. A biologic medication, it is utilised in treating a variety of autoimmune disorders, including rheumatoid arthritis and Crohn’s disease. Among the world’s priciest medications, it brings in billions of dollars annually for AbbVie. Amjevita’s price is expected to be considerably less, potentially facilitating cost savings and augmenting treatment possibilities for patients.

Which Companies Currently Dominate The Competitive Landscape In The Remicade Biosimilar Industry?

Major companies operating in the remicade biosimilar market include Novartis AG, Amgen Inc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Merck And Co. Inc., LG Chem Ltd., Nippon Kayaku Co. Ltd., Celltrion Inc., Nichi-iko Pharmaceutical Co. Ltd., Biocon Limited, Alvotech S.A., MabPharm Ltd., Genor Biopharma Co. Ltd, Shanghai Biomabs Pharmaceuticals Co. Ltd., Samsung Bioepis Co. Ltd., Biocad Biopharmaceutical Co, EPIRUS Biopharmaceuticals Inc., Ranbaxy Laboratories Limited, BioXpress Therapeutics SA, Mabion S.A

https://www.thebusinessresearchcompany.com/report/remicade-biosimilar-global-market-report

Which Geographic Regions Are Driving Demand In The Remicade Biosimilar Market?

Europe was the largest region in the remicade biosimilar market in 2024. The regions covered in the remicade biosimilar market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=11952&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model